NanoViricides Announces 2025 Annual Shareholders Meeting Amid Clinical Development Progress

NanoViricides, Inc. (NYSE American: NNVC) has announced that its Annual Shareholders Meeting will take place at 10 a.m. on Saturday, November 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. The clinical-stage company, which specializes in developing broad-spectrum antiviral drugs designed to prevent viral escape, continues to advance its pipeline of novel therapeutics while maintaining transparency with its investor community through regular shareholder communications.

The company's development efforts center around its nanoviricide technology platform, which creates special purpose nanomaterials for antiviral therapy. This innovative approach is based on intellectual property, technology, and proprietary know-how licensed from TheraCour Pharma, Inc. Under a Memorandum of Understanding with TheraCour, NanoViricides has obtained broad, exclusive, sub-licensable field licenses for drugs developed in several licensed fields, excluding cancer and similar diseases that may have viral origin but require different treatment approaches. The company's business model, established at its foundation in 2005, revolves around licensing technology from TheraCour Pharma Inc. for specific application verticals targeting particular viruses.

NanoViricides' lead drug candidate, NV-387, represents a significant advancement in antiviral treatment development. This broad-spectrum antiviral drug is planned for development as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's other advanced drug candidate, NV-HHV-1, targets the treatment of Shingles. According to company information available at https://www.nanoviricides.com, NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, though the company cannot project an exact date for filing an Investigational New Drug application for any of its drugs due to dependence on external collaborators and consultants.

The company's development pipeline extends beyond its lead candidates to include drugs against numerous viral diseases, demonstrating the breadth of its platform technology. These include oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The platform technology and programs are based on the TheraCour nanomedicine technology, which NanoViricides holds under a worldwide exclusive perpetual license for several drugs with specific targeting mechanisms.

This licensing arrangement covers treatment of multiple human viral diseases: Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company has indicated intentions to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful. Additional company updates and information are available through its newsroom at https://ibn.fm/NNVC.

The development of broad-spectrum antiviral therapeutics carries significant implications for global public health, particularly as emerging viral threats continue to challenge healthcare systems worldwide. NanoViricides' approach to preventing viral escape could represent a crucial advancement in antiviral treatment, potentially addressing the limitation of current therapies that viruses can evolve to resist. However, as the company notes, the path to typical drug development remains extremely lengthy and requires substantial capital, with no assurance that any pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development or that successful laboratory results will translate to successful clinical trials or commercial products.